Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials.

Orbach R, Zhao Z, Wang YC, O'Neill G, Cadavid D.

PLoS One. 2012;7(10):e45409. doi: 10.1371/journal.pone.0045409. Epub 2012 Oct 1.

2.

Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.

Pöhlau D, Przuntek H, Sailer M, Bethke F, Koehler J, König N, Heesen C, Späth P, Andresen I.

Mult Scler. 2007 Nov;13(9):1107-17. Epub 2007 Jul 10.

PMID:
17623736
3.

Natural history of primary progressive multiple sclerosis.

Ebers GC.

Mult Scler. 2004 Jun;10 Suppl 1:S8-13; discussion S13-5. Review.

PMID:
15218804
4.

Clinical and laboratory features of primary progressive and secondary progressive MS.

Bashir K, Whitaker JN.

Neurology. 1999 Sep 11;53(4):765-71.

PMID:
10489038
5.

Natural history of secondary-progressive multiple sclerosis.

Tremlett H, Yinshan Zhao, Devonshire V.

Mult Scler. 2008 Apr;14(3):314-24. doi: 10.1177/1352458507084264. Epub 2008 Jan 21.

PMID:
18208898
6.
7.

Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities.

Tremlett H, Zhao Y, Devonshire V; UBC Neurologists..

J Neurol. 2009 Mar;256(3):374-81. doi: 10.1007/s00415-009-0039-7. Epub 2009 Mar 18.

PMID:
19308306
8.

The natural history of early versus late disability accumulation in primary progressive MS.

Koch MW, Greenfield J, Javizian O, Deighton S, Wall W, Metz LM.

J Neurol Neurosurg Psychiatry. 2015 Jun;86(6):615-21. doi: 10.1136/jnnp-2014-307948. Epub 2014 Aug 4.

PMID:
25091366
9.

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.

Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, Polman C, McFarland H; European (EU-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board.; North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board..

Neurology. 2004 Nov 23;63(10):1779-87.

PMID:
15557490
10.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
11.

Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis.

Leech S, Kirk J, Plumb J, McQuaid S.

Neuropathol Appl Neurobiol. 2007 Feb;33(1):86-98.

PMID:
17239011
12.

Interferon Beta for primary progressive multiple sclerosis.

Rojas JI, Romano M, Ciapponi A, Patrucco L, Cristiano E.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006643. doi: 10.1002/14651858.CD006643.pub3. Review.

PMID:
20091602
13.

Interferon beta for primary progressive multiple sclerosis.

Rojas JI, Romano M, Ciapponi A, Patrucco L, Cristiano E.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006643. doi: 10.1002/14651858.CD006643.pub2. Review. Update in: Cochrane Database Syst Rev. 2010;(1):CD006643.

PMID:
19160292
14.

Modelling the natural history of primary progressive multiple sclerosis.

Harding KE, Wardle M, Moore P, Tomassini V, Pickersgill T, Ben-Shlomo Y, Robertson NP.

J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):13-9. doi: 10.1136/jnnp-2014-307791. Epub 2014 May 14.

PMID:
24828900
15.

Cognitive dysfunction in primary progressive multiple sclerosis: a neuropsychological and MRI study.

Ukkonen M, Vahvelainen T, Hämäläinen P, Dastidar P, Elovaara I.

Mult Scler. 2009 Sep;15(9):1055-61. doi: 10.1177/1352458509106231. Epub 2009 Jun 25.

PMID:
19556313
16.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
17.

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS..

Neurology. 2004 Nov 23;63(10):1788-95.

PMID:
15557491
18.
19.

Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.

Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ, Siva A, Pittock SJ, Pirko I, Keegan BM, Lucchinetti CF, Noseworthy JH, Rodriguez M, Weinshenker BG, Kantarci OH.

Mult Scler. 2013 Feb;19(2):188-98. doi: 10.1177/1352458512451510. Epub 2012 Jun 26.

20.

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.

Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis..

Mult Scler. 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. Epub 2015 Sep 11.

PMID:
26362898

Supplemental Content

Support Center